| Schedule of Finite-Lived Intangible Assets |
Intangible assets, net consisted of the following as of December 31, 2025: | | | | | | | | | | | | | | | | | | | | | | | | | (In thousands) | Weighted
Average Useful
Lives (Years) | | Gross
Carrying
Amount | | Accumulated
Amortization | | Net
Carrying
Amount | Trademarks and trade name | 14 | | $ | 439,121 | | | $ | (99,355) | | | $ | 339,766 | | | Customer/distributor relationships | 11 | | 34,634 | | | (7,795) | | | 26,839 | | Tretinoin distribution and supply agreement | 5 | | 37,176 | | | (24,942) | | | 12,234 | | | Formulations | 8 | | 25,303 | | | (9,921) | | | 15,382 | | | Novaestiq distribution agreement | 20 | | 32,635 | | | — | | | 32,635 | | | Patents | 20 | | 273 | | | (31) | | | 242 | | | Total | | | $ | 569,142 | | | $ | (142,044) | | | $ | 427,098 | |
Intangible assets, net consisted of the following as of December 31, 2024: | | | | | | | | | | | | | | | | | | | | | | | | | (In thousands) | Weighted
Average Useful
Lives (Years) | | Gross
Carrying
Amount | | Accumulated
Amortization | | Net
Carrying
Amount | Trademarks and trade name | 14 | | $ | 559,875 | | | $ | (102,169) | | | $ | 457,706 | | | Customer/distributor relationships | 11 | | 36,000 | | | (6,449) | | | 29,551 | | | Tretinoin distribution and supply agreement | 5 | | 38,900 | | | (18,885) | | | 20,015 | | | Formulations | 8 | | 28,900 | | | (9,943) | | | 18,957 | | | Patents | 20 | | 227 | | | (18) | | | 209 | | | Total | | | $ | 663,902 | | | $ | (137,464) | | | $ | 526,438 | |
|
| Schedule of Expected Amortization Expense |
Expected amortization for each of the years between 2026 through 2030, and thereafter are as follows: (In thousands) | | | | | | Years ending December 31, | | | 2026 | $ | 42,692 | | | 2027 | 39,820 | | | 2028 | 36,001 | | | 2029 | 36,001 | | | 2030 | 34,864 | | | Thereafter | 237,720 | | | $ | 427,098 | |
|